Elicio Therapeutics
Join to apply for the
Assistant Controller
role at
Elicio Therapeutics . Reporting to the VP Finance, this individual will play a critical role in assisting with the day‑to‑day accounting of a fast‑paced biotech company. The Assistant Controller will work independently and lead a team. This position is ideal for someone interested in developing a mix of accounting functions, with a strong sense of urgency, and who can collaborate with cross‑functional teams to deliver timely, accurate work products. Elicio (ELTX) is a growing organization based in the Seaport area of Boston, Massachusetts, with staff also functioning in a virtual‑based environment from the Greater Boston area and throughout the United States. Major Duties / Responsibilities
Financial Management & Reporting
Review and support the clinical accrual process Review the quarterly consolidation and financial statement workbook for SEC reporting Review the monthly/quarterly journal entries and reconciliations Own equity compensation systems, accounting and filings Assist with technical accounting research as needed Lead accounting system implementations as needed Support financial reporting for board meetings Accounting Operations
Oversight and review of the accounting operations Ensure the accounting team adheres to deadlines to ensure a timely close Oversee accounts payable, payroll, expense reporting, and vendor management Assist with updates to formal control documentation to ensure responsibilities are performed in accordance with appropriate internal control requirements Create and update policies and process documents as needed Perform various ad‑hoc accounting tasks and projects as needed to support the finance team Cross‑Functional Collaboration
Lead and develop staff by building engagement with the team, providing feedback and growth opportunities, and holding team accountable; provide mentoring and coaching for direct reports Work directly with the accounting team and business partners to ensure completeness and accuracy of financial information Lead preparation for annual audit and quarterly reviews, including interaction with external auditors and tax consultants Promote a culture of collaboration, cooperation, execution excellence, effective communication and cross‑functional inclusion and problem‑solving to become a high‑performing team member Education & Professional Experience
Degree in Business, Accounting or Finance; CPA is preferred 6‑8 years of relevant accounting experience in biotech or life sciences; prior public accounting experience preferred Experience with Netsuite and Workiva preferred Prior experience managing remote teams is preferred Deep understanding of financial statements Prior SEC reporting experience preferred SOX internal controls experience Ability to work independently as well as with other groups across the business Strong working knowledge in general ledger and GAAP Proficiency in Microsoft Office applications required, including Excel and Word Excellent communication skills, with the ability to collaborate effectively with cross‑functional teams Strong team player with the ability to work in a fast‑paced environment, manage competing priorities, while filling gaps as needed Working Conditions: Busy office/laboratory environment with frequent deadlines and interruptions Travel: Travel is not required Physical Requirements: Subject to periods of sitting or standing; vision is required to monitor data. Work Location: The role can be hybrid or remote (occasional onsite presence is required) Base Salary: $150,000‑$180,000 range on the annual base salary, dependent upon experience About Elicio Therapeutics
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical‑stage biotechnology company advancing a pipeline of novel lymph node‑targeted immunotherapies for the treatment of some of the most aggressive cancers. By combining expertise in immunology and immunotherapy, Elicio is harnessing the natural power of the immune system with the AMP technology, which allows therapeutic payloads to be delivered directly to the lymph nodes, with the goal of enhancing the immune system’s cancer‑fighting capabilities. By targeting cancer immunotherapies to the core of the immune response, AMP aims to optimize the lymph nodes’ natural ability to educate, activate and amplify cancer‑specific T cells, which are essential for recognizing and eliminating tumor cells. Engineered to synchronize immunity in these highly potent sites, AMP is built to enhance the magnitude, potency, quality and durability of the immune response to drive antitumor activity. The Company’s R&D pipeline includes off‑the‑shelf therapeutic cancer immunotherapy ELI‑002 (targeting mKRAS‑driven cancers) as well as ELI‑007 and ELI‑008 (targeting BRAF‑driven cancers and p53 hotspot mutations, respectively). For more information, please visit
www.elicio.com . About The Amphiphile Platform
Elicio Therapeutics’ proprietary Amphiphile (“AMP”) platform delivers investigational immunotherapeutics directly to the “brain center” of the immune system – the lymph nodes. Elicio believes this site‑specific delivery of disease‑specific antigens, adjuvants and other immunomodulators may efficiently educate, activate, and amplify critical immune cells, potentially resulting in induction and persistence of potent adaptive immunity required to treat many diseases. In preclinical models, Elicio has observed lymph node‑specific engagement driving therapeutic immune responses of increased magnitude, function and durability. Elicio believes our AMP lymph node‑targeted approach will produce superior clinical benefits compared to immunotherapies that do not engage the lymph nodes based upon preclinical studies. The AMP platform, originally developed at the Massachusetts Institute of Technology, has broad potential in the cancer space to advance a number of development initiatives through internal activities, in‑licensing arrangements or development collaborations and partnerships.
#J-18808-Ljbffr
Assistant Controller
role at
Elicio Therapeutics . Reporting to the VP Finance, this individual will play a critical role in assisting with the day‑to‑day accounting of a fast‑paced biotech company. The Assistant Controller will work independently and lead a team. This position is ideal for someone interested in developing a mix of accounting functions, with a strong sense of urgency, and who can collaborate with cross‑functional teams to deliver timely, accurate work products. Elicio (ELTX) is a growing organization based in the Seaport area of Boston, Massachusetts, with staff also functioning in a virtual‑based environment from the Greater Boston area and throughout the United States. Major Duties / Responsibilities
Financial Management & Reporting
Review and support the clinical accrual process Review the quarterly consolidation and financial statement workbook for SEC reporting Review the monthly/quarterly journal entries and reconciliations Own equity compensation systems, accounting and filings Assist with technical accounting research as needed Lead accounting system implementations as needed Support financial reporting for board meetings Accounting Operations
Oversight and review of the accounting operations Ensure the accounting team adheres to deadlines to ensure a timely close Oversee accounts payable, payroll, expense reporting, and vendor management Assist with updates to formal control documentation to ensure responsibilities are performed in accordance with appropriate internal control requirements Create and update policies and process documents as needed Perform various ad‑hoc accounting tasks and projects as needed to support the finance team Cross‑Functional Collaboration
Lead and develop staff by building engagement with the team, providing feedback and growth opportunities, and holding team accountable; provide mentoring and coaching for direct reports Work directly with the accounting team and business partners to ensure completeness and accuracy of financial information Lead preparation for annual audit and quarterly reviews, including interaction with external auditors and tax consultants Promote a culture of collaboration, cooperation, execution excellence, effective communication and cross‑functional inclusion and problem‑solving to become a high‑performing team member Education & Professional Experience
Degree in Business, Accounting or Finance; CPA is preferred 6‑8 years of relevant accounting experience in biotech or life sciences; prior public accounting experience preferred Experience with Netsuite and Workiva preferred Prior experience managing remote teams is preferred Deep understanding of financial statements Prior SEC reporting experience preferred SOX internal controls experience Ability to work independently as well as with other groups across the business Strong working knowledge in general ledger and GAAP Proficiency in Microsoft Office applications required, including Excel and Word Excellent communication skills, with the ability to collaborate effectively with cross‑functional teams Strong team player with the ability to work in a fast‑paced environment, manage competing priorities, while filling gaps as needed Working Conditions: Busy office/laboratory environment with frequent deadlines and interruptions Travel: Travel is not required Physical Requirements: Subject to periods of sitting or standing; vision is required to monitor data. Work Location: The role can be hybrid or remote (occasional onsite presence is required) Base Salary: $150,000‑$180,000 range on the annual base salary, dependent upon experience About Elicio Therapeutics
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical‑stage biotechnology company advancing a pipeline of novel lymph node‑targeted immunotherapies for the treatment of some of the most aggressive cancers. By combining expertise in immunology and immunotherapy, Elicio is harnessing the natural power of the immune system with the AMP technology, which allows therapeutic payloads to be delivered directly to the lymph nodes, with the goal of enhancing the immune system’s cancer‑fighting capabilities. By targeting cancer immunotherapies to the core of the immune response, AMP aims to optimize the lymph nodes’ natural ability to educate, activate and amplify cancer‑specific T cells, which are essential for recognizing and eliminating tumor cells. Engineered to synchronize immunity in these highly potent sites, AMP is built to enhance the magnitude, potency, quality and durability of the immune response to drive antitumor activity. The Company’s R&D pipeline includes off‑the‑shelf therapeutic cancer immunotherapy ELI‑002 (targeting mKRAS‑driven cancers) as well as ELI‑007 and ELI‑008 (targeting BRAF‑driven cancers and p53 hotspot mutations, respectively). For more information, please visit
www.elicio.com . About The Amphiphile Platform
Elicio Therapeutics’ proprietary Amphiphile (“AMP”) platform delivers investigational immunotherapeutics directly to the “brain center” of the immune system – the lymph nodes. Elicio believes this site‑specific delivery of disease‑specific antigens, adjuvants and other immunomodulators may efficiently educate, activate, and amplify critical immune cells, potentially resulting in induction and persistence of potent adaptive immunity required to treat many diseases. In preclinical models, Elicio has observed lymph node‑specific engagement driving therapeutic immune responses of increased magnitude, function and durability. Elicio believes our AMP lymph node‑targeted approach will produce superior clinical benefits compared to immunotherapies that do not engage the lymph nodes based upon preclinical studies. The AMP platform, originally developed at the Massachusetts Institute of Technology, has broad potential in the cancer space to advance a number of development initiatives through internal activities, in‑licensing arrangements or development collaborations and partnerships.
#J-18808-Ljbffr